Large neutral amino acid transporter 1 (LAT1) is a solute carrier protein located primarily in the blood-brain barrier (BBB) that offers the potential to deliver drugs to the brain. It is also upregulated in cancer cells, as part of a tumor's increased metabolic demands. Previously, amino acid prodrugs have been shown to be transported by LAT1. Carboxylic acid bioisosteres may afford prodrugs with an altered physicochemical and pharmacokinetic profile than those derived from natural amino acids, allowing for higher brain or tumor levels of drug and/or lower toxicity. The effect of replacing phenylalanine's carboxylic acid with a tetrazole, acylsulfonamide and hydroxamic acid (HA) bioisostere was examined. Compounds were tested for their ability to be LAT1 substrates using both cis-inhibition and trans-stimulation cell assays. As HA-Phe demonstrated weak substrate activity, its structure-activity relationship (SAR) was further explored by synthesis and testing of HA derivatives of other LAT1 amino acid substrates (i.e. Tyr, Leu, Ile, and Met). The potential for a false positive in the trans-stimulation assay caused by parent amino acid was evaluated by conducting compound stability experiments for both HALeu and the corresponding methyl ester derivative. We concluded that HA's are transported by LAT1. In addition, our results lend support to a recent account that amino acid esters are LAT1 substrates, and that hydrogen bonding may be as important as charge for interaction with the transporter binding site.
convoluted as Nagamori et al. reported that several carboxylic esters and a hydroxamic acid derivative of L-leucine were LAT1 substrates. 32 Their conclusions, based in part on a transstimulation assay, 36 contradicted previous reports that esters do not bind LAT1. 4, 24, 37 Our group had been exploring carboxylic acid bioisosteres as LAT1 substrates, including hydroxamic acids 38, 39 as part of our ongoing effort to better understand LAT1 SAR 40 prior to the recent report by Nagamori. 32 We have been focused on modifying the carboxylic acid rather than the amine due to the potential metabolism and toxicity 41 liabilities of the former. Besides contributing to the knowledge of LAT1 SAR, replacing the carboxylic acid functional group has the potential for altering the pharmacokinetics of prodrugs 34, 35 intended for LAT1 transport.
Moreover, learning what functional groups may serve as surrogates for the amino acid carboxyl opens up many possibilities for the design of drugs that might benefit from this delivery mechanism.
Though numerous carboxylic acid bioisosteres have been described, 34, 35, 42, 43 we choose to prioritize the acylsulfonamide, tetrazole, and hydroxamic acid functionalities ( Table 1) . These groups were selected due to their comparable pK a and/or structural similarity to the carboxylic acid functional group, 34 and they have previously demonstrated biological activity in other series. [44] [45] [46] The acylsulfonamide (or sulfonimide) has a similar geometry and pK a as a carboxylic acid, and it was successfully applied as a cysteinyl leukotriene (LTE4) receptor antagonist that demonstrated greater activity than the parent carboxylic acid. 47 Acylsulfonamides were also chosen because they are convenient to synthesize from the corresponding carboxylic acid.
Though slightly larger than a carboxylic acid, 48 tetrazoles faithfully reproduce their trigonal planar shape and acidity (pK a : 4.5−4.9), as the tetrazole anion is stabilized by delocalization. The tetrazole group, which is present in the orally active angiotensin II receptor antagonist Losartan, 46 has the potential to improve oral bioavailability of resulting prodrugs relative to parent carboxylic acid. Hydroxamic acids (pK a : 8−9) are known primarily for their metalchelating abilities; and though dramatically less acidic than the previous two bioisosteres, they have been reported as MAP/ERK kinase inhibitors where they displayed similar ADME properties to carboxylic acids. 44, 49 However, use of hydoxamic acids could be limited by hydrolysis to parent carboxylic acid in vivo. 50 Compounds were evaluated in both cis-inhibition and trans-stimulation assays using HEK cells engineered to overexpress human LAT1. 51, 52 Cis-inhibition studies were used to identify LAT1 transport inhibitors, which may be potential substrates. However, to more directly identify substrates, we performed a trans-stimulation experiment 36 which exploits LAT1's alternating access mechanism 8, 53 by loading cells with a radiolabeled substrate followed by incubation with extracellular test compound. The exchange efflux rate of the radiolabel in the presence of a test compound is compared with the efflux rate in the absence of the test compound. Compounds that are LAT1 substrates should increase the efflux rate of the radiolabeled amino acid compared with its efflux rate in the absence of test compound. We selected [ 3 H]-gabapentin as a probe substrate due to its selectivity for LAT1 relative to other membrane transporters. 8 Acyl sulfonamides 10a-b were prepared from protected amino acids according to methodology described by Drummond. 54 Tetrazole bioisostere 11 was synthesized from the primary amide of Cbz-protected Phe in 3 steps using a previously published route, 55 and our resulting NMR characterization was consistent with what had previously been reported. After discovering a lack of activity for tetrazole 11, we choose not to pursue additional amino acid analogs. Hydroxamic acids (HA's) were synthesized using two different routes. Aromatic analogs (i.e. 12a-12d) were prepared using methodology previously described by Ahlford and Adolfsson. 56 Due to problems with over-reduction of hydroxamic acids to give primary amide (e.g. 13e) during hydrogenolysis of benzyl protected hydroxamic acid, we used a different route to prepare HA's of aliphatic amino acids (Scheme 1).
Hydroxamic acids of aliphatic amino acids Leu, Ile and Met (12e-g) were synthesized according to Scheme 1. Nucleophilic acyl substitution with hydroxylamine on methyl esters 9 gave low yields, but avoided having to use an amine protecting group for Leu and Ile analogs.
However, reaction of 9g with hydroxylamine to form HA-Met gave a complex mixture that could not be purified by recrystallization. We found that Boc protected 9g gave a cleaner conversion to HA-Met, albeit the recrystallized yield was still relatively poor (20% for steps de). Since our objective was to obtain HA's of high purity with negligible levels of parent amino acids to avert a false positive result in our cell assay, we were generally unconcerned about isolated yield and the potential losses resulting from multiple recrystallization steps. Moreover, potentially better methods [57] [58] [59] [60] for preparing HA's were not pursued, as the current routes provided satisfactory amounts of material for testing in a relatively short time period. In contrast, the yield for substitution with ammonia to generate leucinamide 13e was significantly better (60% recrystallized yield) than for the corresponding HA analogs. Generally HA's demonstrated poor solubility in both water and organic solvents; however, we found that solubility was dramatically improved by conversion to the hydrochloride salt. Of these three bioisosteres, only the hydroxamic acid 12a had significant activity in our trans-stimulation assay relative to non-substrates Gly and Arg ( Table 1) . We were surprised by this result. We had expected the tetrazole 11 and acylsulfonamides 10a to have been better surrogates for the acidic carboxylic acid than 12a given that the measured pK a1 values 61 for the former (pK a1 = 2.5 and 1.8, respectively) were much closer to that of parent amino acid Phe 1a
(pK a1 = 1.8) than HA-Phe 12a (pK a1 = 6.9) was. It is worth noting that our pK a1 values were considerably lower than those reported for these bioisosteres when they were present as isolated functional groups, 34 which demonstrates as might be expected that the -amino group depresses their pK a as it would for an adjacent carboxylic acid. conceivable that a similar trend for V max applies to the HA's as it does to the parent amino acids.
However, considering the bounce in our assay relative to the observed efflux rates, we cannot confidently distinguish the substrate activity of the HA's from each other.
Given the disparity in the literature 4, 32, 37 as to whether esters are LAT1 substrates, we also tested the Leu methyl ester 9e, which was an intermediate in the preparation of HA-Leu 12e (Scheme 1). And to further probe the SAR for close-in derivatives of the HA's ( Because of our concerns and those raised by others about the potential for a false positive result in LAT1 cell assays, 37 we evaluated how much parent Leu 1e would need to be present as an impurity in test compounds (i.e. 9e, 12e, or 13e), either from the synthesis or formed under the conditions of the cell assay, to result in a significant efflux rate (>1 fmol/min) in our transstimulation assay. We tested the efflux rate at concentrations ranging from 4 M up to 200 M covering a range of Leu 1e impurity from 2% to 100%, respectively (in relation to previous studies). The background efflux rate (0.7 ± 0.05 fmol/min) was subtracted from total efflux and the net contribution to [ Compelled by the implications of Figure 1 , we carefully scrutinized the purity of all of our HA's by NMR and HPLC (supplementary material), in particular checking for the presence of residual parent amino acid. We recrystallized all of the HA's at least once to improve purity, and the amount of parent amino acid detected by HPLC was less than 0.5%, and in most cases it was below our limit of detection. Thus, we conclude that for the HA's of Table 2 substrate activity was not due to parent amino acid carried over from the synthesis. In addition to being vigilant about purity, we also performed a series of simple stability experiments. Thus, we exposed 13 C-labeled 9e and 12e (Figure 2 ; synthesized using similar methods as described for unlabeled 9e and 12e, above) to conditions to mimic our cell assays, including incubation of compounds with 'buffer only' or with 'buffer and cells' for various periods of time. The resulting mixture was analyzed by 13 C NMR (supplementary material). Within the time period of our cell assay (~5 mins), 13 C-9e hydrolyzed to give 4% parent amino acid, whereas 13 C-12e only gave a marginal increase in parent 13 C-1e relative to its initial amount (0.8% vs. 0.4%, respectively) that was likely within the variability of NMR peak integration. To take the experiment further, we incubated compounds with cells for an hour at 37
°C. This resulted in a moderate increase in the amount of 13 C-1e (12%) from ester 13 C-9e, but only a nominal amount (1%) arising from HA-Leu 13 C-12e hydrolysis. Even after incubation of HA-Leu 13 C-12e with cells for 5h at 37 °C, only 3% 13 C-1e was observed in the 13 C NMR spectrum.
Due to 13 C NMR analysis requirements, these stability experiments had to be performed with 1 mg of compound/well, which was ~25−50X more compound than typically used in our cell assays, done at 200 M concentration. Consequently, we can't rule out the possibility of enzyme saturation at this higher concentration, and that either 9e and/or 12e might be undergoing intracellular enzymatic cleavage as the assay is normally conducted. However, it was previously shown 68 that leucinamide 13e is more sensitive to enzymatic hydrolysis than the leucine methyl ester 12e. So, if enzyme-catalyzed formation of parent Leu was problematic, it seems likely that leucinamide would also have given a false positive; yet, 13e lacked activity in our transstimulation assay.
Upon relating these stability results to Figure 1 , it appears that the concentration of parent Leu 1e within the timeframe of our cell assay from either methyl ester 9e or HA-Leu 12e (~8 and 2 M, respectively) does not explain our trans-stimulation assay results (2.1 and 1.5
fmol/min, respectively). For the observed activity to be solely due to parent amino acid, Figure 1 suggests that Leu would have to be present at ~80 and ~30 M concentrations for 9e and 12e, respectively, and all within the 3 minutes of the assay. Our stability experiments indicated that ≤10% of these levels were actually present, supporting the notion that the observed exchange efflux of [ 3 H]-gabapentin ( Table 2) was mostly caused by the test compounds themselves. Even so, it is probable that a small fraction of the activity was due to Leu, particularly for the less stable methyl ester 9e.
Though the atomic structure of the human LAT1 is not known, we have developed a homology model based on a structure of a related transporter, the arginine-agmatine transporter
AdiC from E. coli. 51, 69 This model has been recently refined using newly characterized ligands and improved LAT1/AdiC alignment. 40 The LAT1 model helped rationalize the amino acid selectivity among amino acid transporters, and virtual screening against this model followed by experimental testing identified previously unknown LAT1 ligands. 51 Docking of 12e against our LAT1 model 40 suggests that hydroxamic acids establish hydrogen bonds with backbone atoms of Ile63 and Gly67 in a manner similar to that of LAT1 amino acid ligands such as leucine ( Figure   3A ). We postulate that maintaining these hydrogen bonds is important for activity, and that this is the primary reason hydroxamic acids are LAT1 substrates. Interestingly, docking of nonligand leucinamide 13e ( Figure 3B) Based on our results and those recently reported by Nagamori, 32 it appears that the previous view that LAT1 substrates must possess an acidic functional group needs to be revised.
As most of the earlier conclusions 4, 37, 73 were based on inhibition experiments (e.g. cis-inhibition or rat brain perfusion) at fixed concentrations of test compound, it is possible that those assays
were not sensitive enough to detect substrates such as esters with weaker interactions with LAT1. The trans-stimulation assay may be more sensitive to identify weak ligands, as it is based on the exchange of pre-loaded substrates (e.g. [ 3 H]-gabapentin) only for test compounds that employ LAT1 to cross a cell membrane, rather than inhibition potency.
Though we do not currently have an explanation for why tetrazoles and acylsulfonamides lacked activity, our data point toward LAT1 binding being less sensitive to the pKa of the carboxylic acid surrogate and more sensitive to its H-bonding capabilities. Thus, our results support the observation made by Nagamori 32 that both oxygens of an amino acid carboxylic acid are likely involved in H-bonding with LAT1. We are currently expanding our work to include additional carboxylic acid bioisosteres 35 to test this hypothesis.
